Recent searches
Search options
Administered by:
New CAR T cell candidate for multiple myeloma has shown an 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial. Additionally, this could be amongst the first CAR products to be administered in the out-patient setting from the start.
https://m-jpost-com.cdn.ampproject.org/c/s/m.jpost.com/health-and-wellness/article-734091/amp
The Jerusalem Post | JPost.com Israeli CAR-T cancer treatment could be administered out-patient The therapy was developed at Hadassah to treat Multiple Myeloma, AL Amyloidosis and other BCMA-positive malignancies.